Salvage chemotherapy with irinotecan and cisplatin in patients with metastatic gastric cancer failing both 5-fluorouracil and taxanes

Anti-Cancer Drugs

Volumn 16, Issue 6, 2005, Pages 621-625

  Park, Se Hoon ^a   Choi, Eun Young ^a   Bang, Soo Mee ^a   Cho, Euk Kyung ^a   Lee, Jae Hoon ^a   Shin, Dong Bok ^a   Lee, Woon Ki ^a   Chung, Min ^a  

^a Gachon University College of Medicine   (South Korea)

Author keywords

Advanced gastric cancer; Cisplatin; Irinotecan

Indexed keywords

CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; IRINOTECAN; PACLITAXEL; TAXANE DERIVATIVE;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; HUMAN; KIDNEY FAILURE; METASTASIS; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OLIGURIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEPTIC SHOCK; SKIN TOXICITY; STOMACH ADENOCARCINOMA; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CISPLATIN; DISEASE PROGRESSION; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; REMISSION INDUCTION; SALVAGE THERAPY; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 20944436198     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200507000-00005     Document Type: Article

References (30)

1. Bae JM, Won YJ, Jung KW, Park JG. Annual report of the Korean central cancer registry program 2000. Cancer Res Treat 2002; 34:77-83.
2. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995; 71:587-591.
3. Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjoden PO, Haglund U, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997; 8:163-168.
4. Van Cutsem E. The treatment of advanced gastric cancer: new findings on the activity of the taxanes. Oncologist 2004; 9(suppl 2):9-15.
5. Kornek GV, Raderer M, Schull B, Fiebiger W, Gedlicka C, Lenauer A, et al. Effective combination chemotherapy with paclitaxel and cisplatin with or without human granulocyte colony-stimulating factor and/or erythropoietin in patients with advanced gastric cancer. Br J Cancer 2002; 86:1858-1863.
6. Roth AD, Maibach R, Martinelli G, Fazio N, Aapro MS, Pagani O, et al. Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO). Ann Oncol 2000; 11:301-306.
7. Ridwelski K, Gebauer T, Fahlke J, Kroning H, Kettner E, Meyer F, et al. Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer. Ann Oncol 2001; 12:47-51.
8. Bokemeyer C, Hartmann JT, Lampe CS, Clemens MR, Quietzsch D, Forkmann L, et al. Paclitaxel and weekly 24-hour infusion of 5-fluorouracil/ folinic acid in advanced gastric cancer. Semin Oncol 1997; 24:96-100.
9. Murad AM, Petroianu A, Guimaraes RC, Aragao BC, Cabral LO, Scalabrini-Neto AO. Phase II trial of the combination of paclitaxel and 5-fluorouracil in the treatment of advanced gastric cancer: a novel, safe, and effective regimen. Am J Clin Oncol 1999; 22:580-586.
10. Ajani JA. Docetaxel in combination for advanced gastric cancer. Gastric Cancer 2002; 5(suppl 1):31-34.
11. Constenla M, Garcia-Arroyo R, Lorenzo I, Carrete N, Campos B, Palacios P. Docetaxel, 5-fluorouracil, and leucovorin as treatment for advanced gastric cancer: results of a phase II study. Gastric Cancer 2002; 5:142-147.
12. Cullinan SA, Moertel CG, Wieand HS, O'Connell MJ, Poon MA, Krook JE, et al. Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. North Central Cancer Treatment Group. J Clin Oncol 1994; 12:412-416.
13. Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: the Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 2003; 21:54-59.
14. Vanhoefer U, Rougier P, Wilke H, Ducreux MP, Lacave AJ, Van Cutsem E, et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 2000; 18:2648-2657.
15. Creemers GJ, Lund B, Verweij J. Topoisomerase I inhibitors: topotecan and irenotecan. Cancer Treat Rev 1994; 20:73-96.
16. Hecht JR, Blanke CD, Benson 3rd AB, Lenz HJ. Irinotecan and paclitaxel in metastatic adenocarcinoma of the esophagus and gastric cardia. Oncology 2003; 17:13-15.
17. Boku N, Ohtsu A, Shimada Y, Shirao K, Seki S, Saito H, et al. Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 1999; 17:319-323.
18. Yoshida M, Boku N, Ohtsu A, Muto M, Nagashima F, Yoshida S. Combination chemotherapy of irinotecan plus cisplatin for advanced gastric cancer: efficacy and feasibility in clinical practice. Gastric Cancer 2001; 4:144-149.
19. Ajani JA, Baker J, Pisters PW, Ho L, Mansfield PF, Feig BW, et al. Irinotecan/ cisplatin in advanced, treated gastric or gastroesophageal junction carcinoma. Oncology 2002; 16:16-18.
20. Hsiang YH, Liu LF, Wall ME, Wani MC, Nicholas AW, Manikumar G, et al. DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues. Cancer Res 1989; 49:4385-4389.
21. Shirao K, Shimada Y, Kondo H, Saito D, Yamao T, Ono H, et al. Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer. J Clin Oncol 1997; 15:921-927.
22. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47:207-214.
23. Ajani JA, Welch SR, Raber MN, Fields WS, Krakoff IH. Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest 1990; 8: 147-159.
24. Park SH, Kim MJ, Chung M, Lee WK, Bang SM, Cho EK, et al. Interim analysis from a prospective randomized trial of taxanes plus 5-FU in advanced gastric cancer. Proc Am Soc Clin Oncol 2004; 22:361 (abstr 4191).
25. Ohtsu A, Yoshida S, Saito D, Shimada Y, Miyamoto K, Fujii T, et al. An early phase II study of 5-fluorouracil combined with cisplatinum as a second line chemotherapy against metastatic gastric cancer. Jpn J Clin Oncol 1991; 21:120-124.
26. Giuliani F, Gebbia V, De Vita F, Maiello E, Di Bisceglie M, Catalane G, et al. Docetaxel as salvage therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico Italia Meridionale (GOIM). Anticancer Res 2003; 23:4219-4222.
27. Schmitz SH, Voliotis DL, Schimke J, Diehl V. Continuous 5-fluorouracil and leucovorin as a second-line therapy for advanced gastric carcinoma. Oncology 1994; 51:502-506.
28. Shimada S, Yagi Y, Kuramoto M, Aoki N, Ogawa M. Second-line chemotherapy with combined irinotecan and low-dose cisplatin for patients with metastatic gastric carcinoma resistant to 5-fluorouracil. Oncol Rep 2003; 10:687-691.
29. Kinoshita K, Yonemura Y, Sawa T, Miyata T, Sakuma H, Matsuki N, et al. 5-Fluorouracil, methotrexate, leucovorin, CDDP and epirubicin (FEPMTX): a wide-spectrum regimen of salvage chemotherapy for high-grade advanced gastric cancer. Hepatogastroenterology 2003; 50: 1716-1719.
30. Chun JH, Kim HK, Lee JS, Choi JY, Lee HG, Yoon SM, et al. Weekly irinotecan in patients with metastatic gastric cancer failing cisplatin-based chemotherapy. Jpn J Clin Oncol 2004; 34:8-13.